文献速递哮喘

基线患者因素对贝那利珠单抗治疗重度哮喘疗效的影响

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
PubMed 文献 · Eur Respir J · 2018-10-18

该分析汇总SIROCCO与CALIMA两项III期研究数据,评估基线因素对贝那利珠单抗疗效的影响。结果显示,口服糖皮质激素使用、鼻息肉和FVC<65%预计值等基线因素可增强贝那利珠单抗Q8W的疗效,尤其在血嗜酸性粒细胞<300·μL-1的患者中。基线临床因素联合血嗜酸性粒细胞计数有助于识别潜在应答者。

要点

  • 贝那利珠单抗Q8W的疗效随基线因素增多而增强,在血嗜酸性粒细胞≥300·μL-1患者中更明显。
  • 口服糖皮质激素使用、鼻息肉和FVC<65%预计值与血嗜酸性粒细胞<300·μL-1患者急性发作率降低的更好应答相关。
  • 基线临床因素和血嗜酸性粒细胞计数可帮助识别贝那利珠单抗潜在应答者。

核心结论

  • 基线临床因素和血嗜酸性粒细胞计数可帮助识别对贝那利珠单抗潜在应答的重度哮喘患者。

研究设计与样本

  • 汇总SIROCCO(NCT01928771)和CALIMA(NCT01914757)两项III期研究数据的分析。
  • 纳入12-75岁接受高剂量吸入糖皮质激素联合长效β2受体激动剂的重度未控制哮喘患者。
  • 患者接受贝那利珠单抗30 mg皮下注射每8周一次(Q8W,前三次每4周一次)、每4周一次(Q4W)或安慰剂。

主要发现

  • 贝那利珠单抗Q8W的治疗效应随每个基线因素增强,在全部患者及血嗜酸性粒细胞≥300·μL-1患者中均相对于总体人群增强。
  • 口服糖皮质激素使用、鼻息肉和FVC<65%预计值与血嗜酸性粒细胞<300·μL-1患者中贝那利珠单抗Q8W降低急性发作率的更好应答相关。

关键数值与推荐

  • 贝那利珠单抗30 mg皮下注射Q8W(前三次Q4W)或Q4W。
  • 基线因素包括口服糖皮质激素使用、鼻息肉、支气管舒张前FVC、既往一年急性发作和诊断年龄。
  • 疗效结局包括年急性发作率和治疗结束时支气管舒张前FEV1相对于安慰剂的变化。

临床怎么用

  • 临床可结合基线因素(如口服糖皮质激素使用、鼻息肉、FVC<65%预计值)和血嗜酸性粒细胞计数评估贝那利珠单抗的潜在应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma.This analysis used pooled data from the SIROCCO (ClinicalTrials.gov identifier NCT01928771) and CALIMA (ClinicalTrials.gov identifier NCT01914757) Phase III studies. Patients aged 12-75 years with severe, uncontrolled asthma receiving high-dosage inhaled corticosteroids plus long-acting β2-agonists received benralizumab 30 mg subcutaneously every 8 weeks (Q8W, first three doses every 4 weeks (Q4W)), Q4W or placebo. Baseline factors that influenced benralizumab efficacy were evaluated, including oral corticosteroid (OCS) use, nasal polyposis, pre-bronchodilator forced vital capacity (FVC), prior year exacerbations and age at diagnosis. Efficacy outcomes included annual exacerbation rate and change in pre-bronchodilator forced expiratory volume in 1 s at treatment end relative to placebo.Benralizumab Q8W treatment effect was enhanced with each baseline factor for all patients and those with ≥300 eosinophils·μL-1 relative to the overall population. OCS use, nasal polyposis and FVC <65% of predicted were associated with greater benralizumab Q8W responsiveness for reduced exacerbation rate for patients with <300 eosinophils·μL-1Baseline clinical factors and blood eosinophil counts can help identify patients potentially responsive to benralizumab.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018. PMID: 30139780. doi:10.1183/13993003.00936-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。